AG
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et) | Frontiers in medicine | 2022 | 235 | 117 | |||
| c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells | EMBO journal | 2022 | 380 | 368 | |||
| PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions | Nature Communications | 2021 | 355 | 187 | |||
| Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment | Cellular & Molecular Immunology | 2021 | 243 | 117 | |||
| Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment | Cell Stress | 2020 | 337 | 150 | |||
| Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma | Cancer Immunology Research | 2020 | 597 | 4 | |||
| Immunophenotyping of human innate lymphoid cells | Methods in Molecular Biology | 2019 | 328 | 1 | |||
| Peripheral innate lymphoid cells are increased in first line metastatic colorectal carcinoma patients: a negative correlation with th1 immune responses | Frontiers in Immunology | 2019 | 325 | 124 | |||
| CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML | Blood Advances | 2019 | 538 | 236 | |||
| Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis | Nature Communications | 2017 | 658 | 171 |
